Oral cholera vaccine

BIOLOGICAL5 trials

Sponsors

Millennium Pharmaceuticals, Inc., Johns Hopkins Bloomberg School of Public Health, International Centre for Diarrhoeal Disease Research, Bangladesh, Helsinki University Central Hospital, MSF OCB

Conditions

CholeraInflammatory Bowel DiseaseTyphoid FeverVaccine ReactionVaccine-Preventable DiseasesVibrio Cholerae Infection

Phase 1

Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab

CompletedNCT01981616

Millennium Pharmaceuticals, Inc.Inflammatory Bowel Disease

Start: 2011-09-30End: 2012-07-31Updated: 2014-07-21

Phase 3

Immunogenicity of Co-administered Oral Polio Vaccine and Oral Cholera Vaccine

International Centre for Diarrhoeal Disease Research, BangladeshVaccine Reaction

Start: 2018-07-01End: 2022-10-25Target: 579Updated: 2022-03-31

Phase 4

Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine

CompletedNCT03373669

Johns Hopkins Bloomberg School of Public HealthCholera, Vibrio Cholerae Infection

Start: 2017-11-16End: 2020-12-01Updated: 2021-04-05

OCV_Delayed Protocol

Active, not recruitingPACTR202206663504683

Start: 2022-06-15Target: 456Updated: 2026-01-27

Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines

CompletedNCT06104345

Helsinki University Central HospitalCholera, Typhoid Fever, Vaccine-Preventable Diseases

Start: 2023-10-25End: 2024-06-26Updated: 2024-12-05

Related Papers

Co-administration of Oral Cholera Vaccine With Oral Polio Vaccine Among Bangladeshi Young Children: A Randomized Controlled Open Label Trial to Assess Interference

Clinical Infectious Diseases2022-09-223 citations

Serum vibriocidal responses when second doses of oral cholera vaccine are delayed 6 months in Zambia.

2021-07-019 citations